Tuesday, December 18, 2018

Federal Court Sides With Novartis And Protects Gilenya Patent From Obviousness-Type Double Patenting

This decision arose from ANDA litigation relating to Novartis’s Gilenya® product for treating multiple sclerosis.
In Novartis AG v. Ezra Ventures LLC, the Federal Circuit addressed “the interplay between a patent term extension (PTE) granted pursuant to 35 U.S.C. § 156 and the obviousness-type double patenting doctrine.” In upholding the Novartis Gilenya patent, the court confirmed that the statute permits an extended product patent to “effectively” block the practice of an earlier-expiring method patent, and refused to elevate the judicially-created doctrine of obviousness-type double patenting over the statutory grant of PTE. Pharmaceutical patent owners will welcome this decision as reinforcing the validity of patents during their PTE term, and may consider how it might apply to similar circumstances raised by a patent term adjustment (PTA) award.

Full length document from pharmapatentsblog....

No comments:

LinkWithin

Related Posts Widget for Blogs by LinkWithin